SEBI has proposed easing norms for NRIs in the derivatives market. It suggests using PAN as a unique identifier to monitor position limits, eliminating the need for CP Codes and the restriction to deal with only one clearing member. Public comments on this consultation paper are open until December 31, 2024.
SEBI has announced that an optional T+0 settlement cycle will be available for the top 500 stocks by market cap from December 31, 2024. Brokers can charge differential fees for T+0 and T+1 cycles. The mechanism includes block deal windows and operational guidelines to ensure smooth implementation.
India’s drug regulator has proposed fast-tracking approvals and waiving local clinical trials for rare disease drugs to improve availability. State regulators have been directed to process approvals within 90 days, facilitate imports, and prioritize testing of rare disease drugs. Waivers may also apply to gene therapies, pandemic drugs, and defense-related drugs approved in major global markets.
